VIEW WEBSITE >>
1 known investors
Theolytics develops oncolytic adenovirus-based immunotherapies to overcome the tumor microenvironment barriers in solid cancers. The company uses its Adenovo platform to identify and advance therapeutic candidates designed to target cancer cells and supporting tissue while enabling immune activation.
BiotechDeep TechMedical Devices